ZIA CP010215 10656 (ZIA) | |||
---|---|---|---|
Title | Colorectal Cancer Studies | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Hildesheim, Allan | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $6,460 | Project Dates | null - null |
Fiscal Year | 2018 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Biochemical Epidemiology (45.0%) Cancer (100.0%) Inflammatory Bowel Disease (15.0%) |
Colon/Rectum (100.0%) | ||
Research Type | |||
Cancer-Related Biology
Technology Development and/or Marker Discovery |
|||
Abstract | |||
Colorectal cancer (CRC) is the 3rd most common cancer in U.S. men and women. Known risk factor associations, such as an increased association with inflammatory bowel disease, and obesity, and decreased association with NSAID use, suggest a role for chronic inflammation in colorectal tumorigenesis. Inflammation can cause or promote tumors through cell proliferation, inhibition of apoptosis and other mechanisms. Studying circulating inflammatory markers could help uncover important molecular pathways that may help elucidate the role of inflammation in the etiology of colorectal cancer. Recently published nested case-control studies of inflammatory markers have revealed some significant findings, but many were underpowered and tested for only a few markers. We propose to test for 88 inflammatory markers in baseline serum samples from 794 CRC cases and 794 controls enrolled in the screening arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial or PLCO. Our objective is to evaluate the association of these inflammatory markers, individually and in aggregate, with the risk of CRC. In addition, we propose to evaluate the markers in relation to CRC risk and genetic factors among controls. If we find significant associations in this study, we will validate the most promising markers (up to 10), using samples from the Women's Health Initiative (WHI), a prospective cohort of over 161,000 women ages 50-79 focused on prevention of various diseases, including colorectal cancer, in postmenopausal women. Identifying inflammatory markers associated with CRC risk will help elucidate the mechanisms by which chronic inflammation contributes to CRC etiology as well as make a significant public health impact in terms of prevention and early detection. |